Okami Medical, the second portfolio company of medical device incubator Inceptus Medical, has raised fresh funds to support the commercialisation of catheter-based technologies for peripheral vascular occlusion.
The company raised $7.2m in a Series D financing round, which was led by US Venture Partners.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The round was also joined by the members of Okami’s board of directors and medical device industry veterans.
Okami’s LOBO Vascular Occlusion System is a single-device solution for the occlusion of a range of arterial targets, eliminating the need for multiple embolic devices.
By combining a patented design with proprietary HDBRAID technology, the system generates a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure.
The technology platform enables the successful treatment of a diverse set of conditions by providing fast and efficient closure of blood vessels throughout the body.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe LOBO system was granted 510(k) clearance by the US Food and Drug Administration (FDA) for the occlusion of peripheral arteries.
Okami president and CEO Bob Rosenbluth said: “We are pleased to continue to work with investors who have supported us in our mission to create and foster innovative concepts into successful companies, including Inari Medical, Sequent Medical and MicroVention.
“We will use these funds to support and accelerate Okami’s commercial and technology development programs.”
Founded in 2017, Okami Medical focuses on the development of intuitive devices for the occlusion of peripheral vessels.
Peripheral vascular occlusion is a circulatory condition caused by reduced blood flow to the limbs due to narrowed blood vessels.
